Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Capital Expenditures: 2010-2025

Historic Capital Expenditures for Heron Therapeutics (HRTX) over the last 9 years, with Jun 2025 value amounting to $208,000.

  • Heron Therapeutics' Capital Expenditures was N/A to $208,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $1.4 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 10.42% up from last year.
  • As of Q2 2025, Heron Therapeutics' Capital Expenditures stood at $208,000, which was up 90.83% from $109,000 recorded in Q1 2025.
  • In the past 5 years, Heron Therapeutics' Capital Expenditures ranged from a high of $1.5 million in Q3 2021 and a low of $45,000 during Q3 2022.
  • Over the past 3 years, Heron Therapeutics' median Capital Expenditures value was $264,000 (recorded in 2023), while the average stood at $366,375.
  • As far as peak fluctuations go, Heron Therapeutics' Capital Expenditures plummeted by 97.06% in 2022, and later skyrocketed by 1,662.22% in 2023.
  • Quarterly analysis of 5 years shows Heron Therapeutics' Capital Expenditures stood at $390,000 in 2021, then increased by 6.15% to $414,000 in 2022, then crashed by 39.61% to $250,000 in 2023, then skyrocketed by 155.20% to $638,000 in 2024, then reached $208,000 in 2025.
  • Its last three reported values are $208,000 in Q2 2025, $109,000 for Q1 2025, and $638,000 during Q4 2024.